Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BAG3
REST API REST API
Homo sapiens
BAG3 is differentially expressed in 256 experiments: 116 organism parts: bone marrow, heart, ... (114 more);, 182 disease states: normal, Huntington's disease, ... (180 more);, 91 cell types 416 cell lines 34 compound treatments and 67 other conditions.
Orthologs BAG3 (Bos taurus)   Bag3 (Rattus norvegicus)   ENSCING00000007522 (Ciona intestinalis)   Bag3 (Mus musculus)   bag3 (Danio rerio)   stv (Drosophila melanogaster)   Q5ZIY1_CHICK (Gallus gallus)   bag3 (Xenopus laevis)   BAG3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, negative regulation of apoptosis, protein folding, chaperone binding, anti-apoptosis, synaptosome, brain development, spinal cord development
InterPro Term WW_Rsp5_WWP, BAG_domain
UniProt Accession O95817, C9JFK9
Gene-Disease Assocation CARDIOMYOPATHY, DILATED, 1HH; CMD1HH, MYOPATHY, MYOFIBRILLAR 6, MFM6
Search EB-eye ENSG00000151929
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (34 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
KG1
2
E-MTAB-37, E-GEOD-24147
MCF7
2
E-GEOD-5258, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
410 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-13909, ... (47 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-GEOD-6740, E-MTAB-25
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
not specified
2
E-GEOD-18811, E-GEOD-11755
stromal cell
2
E-GEOD-1460, E-MEXP-2034
CD4+ T cell
2
3
E-GEOD-6740, E-GEOD-16190, E-MEXP-1600, E-MTAB-24, E-MTAB-25 ... (5 experiments)
monocyte
1
2
E-MEXP-583, E-GEOD-995, E-MEXP-2019
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2508, E-GEOD-16363, E-MTAB-62, ... (41 experiments)

Factor Value U/D Experiments
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
colon carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
obesity
2
E-MTAB-62, E-GEOD-2508
176 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-5099, E-GEOD-6462, E-MEXP-1958, ... (19 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-6907, E-MEXP-1958, E-GEOD-20719, E-GEOD-7400, E-MEXP-1601, ... (6 experiments)
M-CSF
1
E-GEOD-5099
Cxcl12
1
E-GEOD-7307
hydrogen peroxide
1
E-GEOD-5339
control - untreated
1
E-GEOD-7216
TTA
1
E-MEXP-2590
28 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
127.57
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-21750, E-GEOD-22593, E-GEOD-2292, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-1290, E-MEXP-2069, ... (23 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-21750, ... (9 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246, E-GEOD-20037

Replicate
studied in E-GEOD-18791, E-GEOD-17204

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.372 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM